Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

SELL
$16.26 - $21.73 $1.7 Million - $2.27 Million
-104,424 Reduced 56.55%
80,236 $1.37 Million
Q4 2022

Feb 10, 2023

SELL
$16.98 - $23.15 $101,880 - $138,900
-6,000 Reduced 3.15%
184,660 $3.69 Million
Q3 2022

Nov 09, 2022

SELL
$20.88 - $28.21 $1.55 Million - $2.09 Million
-74,217 Reduced 28.02%
190,660 $4.11 Million
Q2 2022

Aug 09, 2022

SELL
$17.07 - $25.71 $343,107 - $516,771
-20,100 Reduced 7.05%
264,877 $5.22 Million
Q1 2022

May 09, 2022

BUY
$20.42 - $28.13 $1.01 Million - $1.39 Million
49,432 Added 20.99%
284,977 $6.7 Million
Q4 2021

Feb 10, 2022

SELL
$25.89 - $33.45 $2.67 Million - $3.44 Million
-102,958 Reduced 30.42%
235,545 $6.42 Million
Q3 2021

Nov 10, 2021

SELL
$22.46 - $29.47 $174,469 - $228,922
-7,768 Reduced 2.24%
338,503 $9.32 Million
Q2 2021

Aug 10, 2021

SELL
$24.17 - $36.01 $590,183 - $879,292
-24,418 Reduced 6.59%
346,271 $9.85 Million
Q1 2021

May 03, 2021

BUY
$32.28 - $44.3 $2.16 Million - $2.96 Million
66,787 Added 21.98%
370,689 $12.6 Million
Q4 2020

Feb 05, 2021

SELL
$31.45 - $40.54 $1.79 Million - $2.31 Million
-56,927 Reduced 15.78%
303,902 $10.1 Million
Q3 2020

Nov 12, 2020

BUY
$26.0 - $34.5 $1.2 Million - $1.6 Million
46,321 Added 14.73%
360,829 $11.6 Million
Q2 2020

Jul 28, 2020

BUY
$14.11 - $29.42 $2.18 Million - $4.55 Million
154,807 Added 96.94%
314,508 $8.66 Million
Q1 2020

May 07, 2020

BUY
$13.63 - $33.98 $1.73 Million - $4.32 Million
127,104 Added 389.93%
159,701 $2.56 Million
Q4 2019

May 07, 2020

BUY
$16.12 - $24.98 $525,463 - $814,273
32,597 New
32,597 $778,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.48B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Sycale Advisors (Ny) LLC Portfolio

Follow Sycale Advisors (Ny) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sycale Advisors (Ny) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sycale Advisors (Ny) LLC with notifications on news.